Drug intelligence / Profile preview

WR909390

Development stage: Phase 1
Lead developer: Walter Reed Army Institute of Research
Modality: Small Molecules
Administration: Oral

Overview

WR909390 is a small molecule drug developed by the Walter Reed Army Institute of Research for the treatment of infectious diseases, with a primary focus on malaria. It belongs to the triazine class of compounds and was evaluated in an early phase 1 clinical trial to assess its pharmacokinetics and bioavailability. The compound has not yet received regulatory approval, and its highest development status is "pending." The U.S. Army Medical Research & Development Command has also been involved in its development[1][2].

Beyond the preview

Go deeper on WR909390.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WR909390.

Explore the full profile